Sanofi to Present Data on Rilzabrutinib for ITP and Hemophilia Therapies ALTUVIIIO and Qfitlia at 2025 ISTH Congress

Sanofi will present new data from 18 abstracts, including five oral presentations, at the 33rd Congress of the International Society on Thrombosis and Haemostasis (ISTH) in Washington D.C., scheduled to take place from June 21 to 25, 2025. The findings focus on advancements in treatments for rare blood disorders, with key highlights including research on rilzabrutinib for immune thrombocytopenia (ITP) and updates on hemophilia therapies ALTUVIIIO and Qfitlia. These developments aim to expand treatment options and address underlying disease mechanisms.

The data related to rilzabrutinib explore its potential in targeting immune dysregulation associated with ITP, a condition characterized by low platelet counts due to an autoimmune response. Additionally, Sanofi will showcase progress in hemophilia care through ALTUVIIIO and Qfitlia, which were recently launched as part of efforts to improve therapeutic outcomes for patients living with rare blood diseases. The presentations underscore ongoing innovation within Sanofi’s pipeline aimed at addressing unmet medical needs in these areas.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

Date: June 6, 2025

Related posts:

Navigating Drug Patents: A Comprehensive Strategy Involves Monitoring New Filings, Expirations, and Litigation. STAT Health Tech: Trump-Era AI Memos’ Impact on Healthcare Analyzed, Plus Sector News Two Drug Candidates Identified for Treating Ultra-Rare XMEA Using Zebrafish Model USP Opens Advanced Technology Laboratory in Maryland to Improve Medicine Production and Supply Chain

Author

Mark Chiang